Sage Therapeutic Stock Net Income
| SAGE Stock | USD 13.94 0.83 6.33% |
Sage Therapeutic fundamentals help investors to digest information that contributes to Sage Therapeutic's financial success or failures. It also enables traders to predict the movement of Sage Stock. The fundamental analysis module provides a way to measure Sage Therapeutic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sage Therapeutic stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -541.5 M | -514.4 M | |
| Net Loss | -655.9 M | -623.1 M | |
| Net Loss | -479.5 M | -455.5 M | |
| Net Loss | (9.05) | (9.50) | |
| Net Income Per E B T | 1.09 | 1.06 |
Sage | Net Income |
Sage Therapeutic Company Net Income Analysis
Sage Therapeutic's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Sage Therapeutic Net Income | (541.49 M) |
Most of Sage Therapeutic's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sage Therapeutic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sage Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Sage Therapeutic is extremely important. It helps to project a fair market value of Sage Stock properly, considering its historical fundamentals such as Net Income. Since Sage Therapeutic's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sage Therapeutic's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sage Therapeutic's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Sage Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Sage Therapeutic reported net income of (541.49 Million). This is 258.66% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 194.84% higher than that of the company.
Sage Therapeutic Current Valuation Drivers
We derive many important indicators used in calculating different scores of Sage Therapeutic from analyzing Sage Therapeutic's financial statements. These drivers represent accounts that assess Sage Therapeutic's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Sage Therapeutic's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 3.7B | 4.5B | 2.5B | 2.3B | 1.3B | 2.0B | |
| Enterprise Value | 3.6B | 2.9B | 2.2B | 2.1B | 1.2B | 1.8B |
Sage Therapeutic Institutional Holders
Institutional Holdings refers to the ownership stake in Sage Therapeutic that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Sage Therapeutic's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Sage Therapeutic's value.| Shares | Palo Alto Investors, Llc | 2023-12-31 | 991.5 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 967.7 K | Goldman Sachs Group Inc | 2023-12-31 | 953 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 870.6 K | Samlyn Capital, Llc | 2023-12-31 | 768.9 K | Northern Trust Corp | 2023-12-31 | 542.7 K | Alyeska Investment Group, L.p. | 2023-09-30 | 528.8 K | T. Rowe Price Associates, Inc. | 2023-12-31 | 478.1 K | Fisher Asset Management, Llc | 2023-12-31 | 431.9 K | Wellington Management Company Llp | 2023-12-31 | 6.1 M | Fmr Inc | 2023-12-31 | 5.5 M |
Sage Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (14.89) % | ||||
| Current Valuation | 125.23 M | ||||
| Shares Outstanding | 60.18 M | ||||
| Shares Owned By Insiders | 12.40 % | ||||
| Shares Owned By Institutions | 94.25 % | ||||
| Number Of Shares Shorted | 9.31 M | ||||
| Price To Earning | 3.07 X | ||||
| Price To Book | 1.16 X | ||||
| Price To Sales | 10.73 X | ||||
| Revenue | 86.45 M | ||||
| Gross Profit | (319.29 M) | ||||
| EBITDA | (511.68 M) | ||||
| Net Income | (541.49 M) | ||||
| Cash And Equivalents | 1.51 B | ||||
| Cash Per Share | 25.47 X | ||||
| Total Debt | 5.17 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 17.69 X | ||||
| Book Value Per Share | 11.73 X | ||||
| Cash Flow From Operations | (540.59 M) | ||||
| Short Ratio | 11.22 X | ||||
| Earnings Per Share | (8.39) X | ||||
| Price To Earnings To Growth | 0.74 X | ||||
| Target Price | 21.88 | ||||
| Number Of Employees | 487 | ||||
| Beta | 0.85 | ||||
| Market Capitalization | 838.94 M | ||||
| Total Asset | 882.28 M | ||||
| Retained Earnings | (2.57 B) | ||||
| Working Capital | 786.6 M | ||||
| Current Asset | 188.49 M | ||||
| Current Liabilities | 15.31 M | ||||
| Net Asset | 882.28 M |
About Sage Therapeutic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sage Therapeutic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sage Therapeutic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sage Therapeutic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:Check out Sage Therapeutic Piotroski F Score and Sage Therapeutic Altman Z Score analysis. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.Note that the Sage Therapeutic information on this page should be used as a complementary analysis to other Sage Therapeutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Sage Stock analysis
When running Sage Therapeutic's price analysis, check to measure Sage Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sage Therapeutic is operating at the current time. Most of Sage Therapeutic's value examination focuses on studying past and present price action to predict the probability of Sage Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sage Therapeutic's price. Additionally, you may evaluate how the addition of Sage Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Sage Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.39) | Revenue Per Share 1.519 | Quarterly Revenue Growth 1.399 | Return On Assets (0.32) | Return On Equity (0.55) |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.